Updated 12 hours ago
Last progress July 4, 2025 (7 months ago)
Stops Federal Medicaid and CHIP from paying for a set of gender-transition medical services by changing existing law. It identifies certain surgeries, implants, and medications as excluded from coverage, creates narrow medical exceptions (such as treatment for some medical disorders and treatment for precocious puberty with parental/guardian consent), and sets definitions for “sex,” “female,” and “male” to apply to the rule. The change mainly affects Medicaid and CHIP enrollees who seek gender‑affirming care, health providers who deliver those services, and state Medicaid programs that administer benefits. It may reduce federal coverage for gender-transition treatments except where a specified medical exception applies.
Amends section 1903(i) of title 42 (42 U.S.C. 1396b(i)) to add paragraph (28) that disallows Federal Medicaid payments with respect to any amount expended for specified gender transition procedures furnished to an individual enrolled in a State plan (or waiver of such plan).
Amends section 2107(e)(1)(N) of title 42 (42 U.S.C. 1397gg(e)(1)(N)) by inserting paragraph (28) into the listed items, thereby aligning CHIP funding rules with the new Medicaid prohibition.
Adds a new subsection (kk) to section 1905 of title 42 (42 U.S.C. 1396d) that defines “specified gender transition procedures.” The definition lists specific surgeries (e.g., castration, orchiectomy, metoidioplasty, phalloplasty, vaginoplasty, mastectomy, etc.); any plastic, cosmetic, or aesthetic surgery that feminizes or masculinizes facial or other body features; placement of chest implants or erection/testicular prostheses; placement of fat or artificial implants in the gluteal region; and administering, prescribing, or dispensing certain medications (including GnRH analogues/puberty blockers and supraphysiologic doses of testosterone, estrogen, or other androgens).
Creates exceptions to the definition: Paragraph (1) does not apply when the procedure or treatment is furnished by a health care provider with the consent of the individual's parent or legal guardian for (A) puberty suppression drugs to normalize puberty for an individual experiencing precocious puberty; or (B) medically necessary procedures or treatments to correct a medically verifiable disorder of sex development (lists specific chromosome examples), abnormalities of sex chromosome structure or sex steroid production/action as determined by physician testing, procedures to treat infection/disease/injury caused or worsened by a prior listed procedure or to prevent imminent danger of death or major bodily-function impairment (excluding procedures performed solely to alleviate mental distress), or procedures to restore or reconstruct the body to correspond to the individual's sex after previous procedures (may include removal of a pseudo phallus or breast augmentation). These exceptions require parent or legal guardian consent when furnished to an individual.
Defines the term “sex” for purposes of paragraph (1) to mean either male or female, with separate definitions: (4) “female” means an individual who naturally has, had, will have, or would have (but for developmental or genetic anomaly or historical accident) the reproductive system that at some point produces, transports, and utilizes eggs for fertilization; (5) “male” means an individual who naturally has, had, will have, or would have (but for developmental or genetic anomaly or historical accident) the reproductive system that at some point produces, transports, and utilizes sperm for fertilization.
Who is affected and how:
Medicaid and CHIP enrollees seeking gender‑affirming care: Most directly affected; coverage for a set of surgeries, implants, and medications identified in the law would be disallowed under Federal rules, meaning those services could be denied or require out‑of‑pocket payment unless they meet a listed exception.
Transgender people (including minors and adults): Reduced federal coverage likely lowers access to medically recommended gender‑affirming treatments for enrollees who rely on Medicaid/CHIP; minors may face particular restrictions except in the narrow precocious puberty exception with parental/guardian consent.
Parents and guardians of minors: May face limits on Medicaid/CHIP coverage for transition-related care for children; the statute preserves a specific limited exception for precocious puberty with consent, which narrows coverage options for other kinds of gender-identity-related treatment.
Health care providers and clinics: Will confront changed reimbursement rules; providers may need to modify care pathways, prior authorization practices, and billing for Medicaid/CHIP patients. Some providers may choose not to offer certain services to Medicaid/CHIP enrollees if coverage is barred.
State Medicaid programs and administrators: Must implement the federal coverage change in their programs, revise state plans and notices, and handle appeals and exceptions; this creates administrative workload and program adjustments.
Broader system effects: Possible increases in uncompensated care, shifts to private-pay arrangements where feasible, potential legal challenges over coverage denials and the statutory definitions, and impacts on clinical guidelines and professional practice for treating gender dysphoria and related conditions.
Limitations and uncertainties:
The text preserves specific narrow exceptions but does not broadly preserve coverage for gender‑affirming care; precise application will depend on how exceptions are interpreted and implemented by agencies and courts.
The section alters statutory definitions of sex/male/female for the purpose of the rule, which could have effects beyond coverage decisions depending on administrative interpretation, but the immediate, clear effect is on Medicaid/CHIP payment eligibility.
Read twice and referred to the Committee on Finance.
Last progress June 10, 2025 (8 months ago)
Introduced on June 10, 2025 by John Cornyn